Company: DNLI
Filing Date: 2025-02-27
Form Type: 8-K
Source: 0001714899-25-000067
Chunk: 1

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 8-K
Item: Item 1.01
Chunk 1
---
 the Agreement.

In the Agreement, the Company has agreed to indemnify the sales agents against certain liabilities, including under the Securities Act and to contribute payments that the sales agents may be required to make because of such liabilities. Further, the sales agents have agreed to indemnify the Company, the Company’s board of directors and its executive officers against certain liabilities, including under the Securities Act.

The shares of common stock sold pursuant to the Agreement will be issued pursuant to the Company’s shelf registration statement on Form S-3ASR, including the prospectus supplement contained therein, filed with the Securities and Exchange Commission (the “ SEC”) on February 27, 2025, which was automatically effective upon filing with the SEC.

The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Item 1.02 Termination of a Material Definitive Agreement